Trial Profile
Dose scale-up and cohort expansion study with the therapeutic mAb 14F7 (Anti-Nglicolil GM3) in patients with solid tumors at advanced stages
Status:
Not yet recruiting
Phase of Trial:
Phase I
Latest Information Update: 18 Oct 2020
Price :
$35
*
At a glance
- Drugs Monoclonal antibody 14F7 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 29 Aug 2016 New trial record